Phase 4
N=50
A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients
Tracheal Extubation
Bottom Line
View on ClinicalTrials.gov: NCT01152515 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Mean Arterial Pressure Changes During Extubation — 94; 97; 96; 97 mmHg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Remifentanil (Drug)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Severance Hospital
- Primary completion
- Feb 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Arterial Pressure Changes During Extubation |
94; 97; 96; 97 | — |
| PRIMARY HR Changes During Extubation |
94; 95; 94; 93 | — |
| PRIMARY The Grade of Coughing During Extubation |
8; 11; 11; 9; 4; 3 | — |
| SECONDARY Time of Awake |
3.5; 4 | — |
| SECONDARY Time of Extubation |
8; 14 | — |
Summary
Tracheal extubation can be associated with hyperdynamic circulatory response. The investigators examined the effect of maintaining a remifentanil infusion on the cardiovascular response during extubation in propofol-remifentanil sedated patients after surgery.
Eligibility Criteria
Inclusion Criteria
- Age ≥ 20
- Short term ventilator care after surgery in intensive care unit
Exclusion Criteria
- pneumonia
- chronic obstructive lung disease
- asthma
- end stage renal disease
- risk factors for aspiration
Data sourced from ClinicalTrials.gov (NCT01152515). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.